Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

Cancer Cell. 2020 Feb 10;37(2):258-259. doi: 10.1016/j.ccell.2020.01.010.
No abstract available

Publication types

  • Published Erratum